SpectraCure AB - Asset Resilience Ratio
SpectraCure AB (SPEC) has an Asset Resilience Ratio of 22.93% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read SPEC current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how SpectraCure AB's Asset Resilience Ratio has changed over time. See SPEC book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down SpectraCure AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SpectraCure AB market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr25.51 Million | 22.93% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr25.51 Million | 22.93% |
Asset Resilience Insights
- Good Liquidity Position: SpectraCure AB maintains a healthy 22.93% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
SpectraCure AB Industry Peers by Asset Resilience Ratio
Compare SpectraCure AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055 |
Medical Devices | 4.92% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
MODULIGHT OY EO 1
F:78W |
Medical Devices | 22.31% |
|
Diagnostic Medical Systems SA
PA:ALDMS |
Medical Devices | 1.39% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Nova EYE Medical Ltd
AU:EYE |
Medical Devices | 11.08% |
Annual Asset Resilience Ratio for SpectraCure AB (2016–2024)
The table below shows the annual Asset Resilience Ratio data for SpectraCure AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.10% | Skr18.27 Million ≈ $1.97 Million |
Skr121.00 Million ≈ $13.02 Million |
-24.22pp |
| 2023-12-31 | 39.32% | Skr56.95 Million ≈ $6.13 Million |
Skr144.83 Million ≈ $15.59 Million |
-18.05pp |
| 2022-12-31 | 57.37% | Skr93.18 Million ≈ $10.03 Million |
Skr162.42 Million ≈ $17.48 Million |
-10.70pp |
| 2021-12-31 | 68.07% | Skr129.69 Million ≈ $13.96 Million |
Skr190.52 Million ≈ $20.50 Million |
-6.61pp |
| 2020-12-31 | 74.69% | Skr157.24 Million ≈ $16.92 Million |
Skr210.53 Million ≈ $22.66 Million |
+20.58pp |
| 2019-12-31 | 54.10% | Skr54.21 Million ≈ $5.83 Million |
Skr100.19 Million ≈ $10.78 Million |
-11.27pp |
| 2018-12-31 | 65.38% | Skr45.08 Million ≈ $4.85 Million |
Skr68.95 Million ≈ $7.42 Million |
+48.79pp |
| 2017-12-31 | 16.59% | Skr2.44 Million ≈ $262.60K |
Skr14.71 Million ≈ $1.58 Million |
+15.26pp |
| 2016-12-31 | 1.33% | Skr381.67K ≈ $41.07K |
Skr28.77 Million ≈ $3.10 Million |
-- |
About SpectraCure AB
SpectraCure AB (publ) engages in the development of cancer treatment system in Sweden. It develops Q-PRO, a laser unit; IDOSE software platform, which calculates the optimal laser light dose and placement of the optical fibers; and disposable items comprising needles, optical fibers, and light-sensitive medication. The company was incorporated in 2003 and is based in Lund, Sweden.